Sabra Healthcare REIT (SBRA)
(Real Time Quote from BATS)
$16.26 USD
-0.42 (-2.52%)
Updated Aug 12, 2024 03:44 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SBRA 16.26 -0.42(-2.52%)
Will SBRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SBRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SBRA
Sabra (SBRA) Reports Q2 Earnings: What Key Metrics Have to Say
Sabra Healthcare (SBRA) Q2 FFO and Revenues Top Estimates
SBRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sabra (SBRA) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
DiamondRock Hospitality (DRH) Beats Q2 FFO and Revenue Estimates
Four Corners Property Trust (FCPT) Matches Q2 FFO Estimates
Other News for SBRA
REITs keep reducing NAV discount amid an impending rally
The Return Of Volatility
Sabra Healthcare REIT: A Strong Buy on Robust Financial Performance and Growth Prospects
Sabra Healthcare REIT: A Balanced Hold Rating Amid Growth and Challenges
JMP Securities Sticks to Its Hold Rating for Sabra Healthcare REIT (SBRA)